paracetamol: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
paracetamol: clinical details
Prescribing considerations
- Reconcile total paracetamol exposure from every prescribed, administered and self-selected product and from all routes.
- Assess liver and kidney function, body weight, nutrition, hydration, alcohol history and concurrent enzyme-inducing medicines when relevant.
- Intravenous prescribing requires an accurate current weight and clear expression of both mass and volume to reduce errors.
- Consider product-specific excipients, including sodium, glucose, sorbitol, maltitol, preservatives, colourings and sulphites.
- Suspect pyroglutamic acidosis in unexplained high-anion-gap metabolic acidosis in a high-risk patient receiving paracetamol, especially with flucloxacillin.
Contraindications and cautions
- Hypersensitivity to paracetamol or a formulation ingredient.
- Severe hepatocellular insufficiency is a contraindication to the selected intravenous product.
- Selected suppositories contain soya oil and are contraindicated with peanut or soya allergy.
- Certain oral suspensions containing sorbitol or maltitol are unsuitable in hereditary fructose intolerance.
Monitoring
- No routine laboratory monitoring is specified for uncomplicated short-term labelled use.
- Monitor INR more closely during prolonged regular use with warfarin or another coumarin anticoagulant.
- For intravenous treatment, verify weight, cumulative exposure from all routes, infusion administration and relevant renal, hepatic and metabolic risk factors.
- If pyroglutamic acidosis is suspected, stop paracetamol promptly, assess acid–base status and consider urinary 5-oxoproline testing.
Clinical pharmacology
Paracetamol has central analgesic and antipyretic activity associated with inhibition of prostaglandin synthesis. Oral paracetamol is rapidly absorbed, undergoes predominantly hepatic conjugation and is excreted mainly in urine. A small reactive metabolite becomes clinically important when glutathione-dependent detoxification is overwhelmed or impaired.
Formulation and product differences
- Oral suspensions require shaking and accurate volume measurement; excipients and licensed age ranges differ between products.
- Suppositories provide a rectal option when oral administration is difficult, but excipients such as soya oil may create product-specific contraindications.
- Intravenous solution is reserved for clinically justified parenteral use and carries particular risks from weight- or volume-calculation errors.
- Panadol ActiFast contains substantial sodium bicarbonate, affecting sodium exposure and absorption characteristics.
- Tablet excipients differ; the selected generic tablet contains sodium metabisulphite, which may matter in susceptible patients.
paracetamol preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 10 mg/mL, 1 g/100 mL
Caplet
Route: Oral
Strengths: 500 mg
Capsule
Route: Oral
Strengths: 500 mg
paracetamol interactions
Check prescribed and non-prescribed medicines, particularly combination cold, flu and pain products.
Other paracetamol-containing medicines
Combining products can unintentionally cause overdose and serious liver injury.
Warfarin and other coumarin anticoagulants
Prolonged regular paracetamol use may increase anticoagulant effect and bleeding risk, so closer INR monitoring may be needed; occasional use has less effect.
Flucloxacillin
Concurrent use can contribute to pyroglutamic acidosis, particularly in severely ill, malnourished, renally impaired or otherwise glutathione-depleted patients.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.